225 related articles for article (PubMed ID: 1705232)
1. Vimentin, carcinoembryonic antigen and keratin in the diagnosis of mesothelioma, adenocarcinoma and reactive pleural lesions.
al-Saffar N; Hasleton PS
Eur Respir J; 1990 Oct; 3(9):997-1001. PubMed ID: 1705232
[TBL] [Abstract][Full Text] [Related]
2. Reactive lesions of the pleura. Immunohistochemical characterization.
Brockmann M; Brockmann I; Fischer M; Müller KM
Pathol Res Pract; 1990 Apr; 186(2):238-46. PubMed ID: 1692994
[TBL] [Abstract][Full Text] [Related]
3. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical differentiation of malignant mesothelioma, mesothelial hyperplasia and metastatic adenocarcinoma in serous effusions, utilizing staining for carcinoembryonic antigen, keratin and vimentin.
Duggan MA; Masters CB; Alexander F
Acta Cytol; 1987; 31(6):807-14. PubMed ID: 2447718
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical and histochemical markers of primary lung cancer, lung metastases, and pleural mesotheliomas.
Popper H; Wirnsberger G; Hoefler H; Denk H
Cancer Detect Prev; 1987; 10(3-4):167-74. PubMed ID: 2436780
[TBL] [Abstract][Full Text] [Related]
6. The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma.
Ordóñez NG
Am J Surg Pathol; 1989 Apr; 13(4):276-91. PubMed ID: 2648877
[TBL] [Abstract][Full Text] [Related]
7. Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.
Friedman MT; Gentile P; Tarectecan A; Fuchs A
Arch Pathol Lab Med; 1996 Oct; 120(10):959-66. PubMed ID: 12046609
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.
Roberts F; Harper CM; Downie I; Burnett RA
Am J Clin Pathol; 2001 Aug; 116(2):253-62. PubMed ID: 11488073
[TBL] [Abstract][Full Text] [Related]
9. Immunocytochemical differential diagnosis of diffuse malignant pleural mesotheliomas--a clinicomorphological study of 158 cases.
Vortmeyer AO; Preuss J; Padberg BC; Kastendieck H; Schröder S
Anticancer Res; 1991; 11(2):889-94. PubMed ID: 1712181
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical evaluation of seven monoclonal antibodies for differentiation of pleural mesothelioma from lung adenocarcinoma.
Wirth PR; Legier J; Wright GL
Cancer; 1991 Feb; 67(3):655-62. PubMed ID: 1702354
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical staining for keratin and carcinoembryonic antigen in the diagnosis of malignant mesothelioma.
Holden J; Churg A
Am J Surg Pathol; 1984 Apr; 8(4):277-9. PubMed ID: 6201076
[TBL] [Abstract][Full Text] [Related]
12. Mesothelioma: profile of keratin proteins and carcinoembryonic antigen: an immunoperoxidase study of 20 cases and comparison with pulmonary adenocarcinomas.
Corson JM; Pinkus GS
Am J Pathol; 1982 Jul; 108(1):80-8. PubMed ID: 6178295
[TBL] [Abstract][Full Text] [Related]
13. The value of cytokeratins 20 and 7 in discriminating metastatic adenocarcinomas from pleural mesotheliomas.
Tot T
Cancer; 2001 Nov; 92(10):2727-32. PubMed ID: 11745209
[TBL] [Abstract][Full Text] [Related]
14. Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients.
Kayser K; Böhm G; Blum S; Beyer M; Zink S; André S; Gabius HJ
J Pathol; 2001 Feb; 193(2):175-80. PubMed ID: 11180163
[TBL] [Abstract][Full Text] [Related]
15. Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura.
Cury PM; Butcher DN; Fisher C; Corrin B; Nicholson AG
Mod Pathol; 2000 Feb; 13(2):107-12. PubMed ID: 10697265
[TBL] [Abstract][Full Text] [Related]
16. Antigenic phenotype of malignant mesotheliomas and pulmonary adenocarcinomas. An immunohistologic analysis demonstrating the value of Leu M1 antigen.
Sheibani K; Battifora H; Burke JS
Am J Pathol; 1986 May; 123(2):212-9. PubMed ID: 2422942
[TBL] [Abstract][Full Text] [Related]
17. The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3).
Szpak CA; Johnston WW; Roggli V; Kolbeck J; Lottich SC; Vollmer R; Thor A; Schlom J
Am J Pathol; 1986 Feb; 122(2):252-60. PubMed ID: 2418688
[TBL] [Abstract][Full Text] [Related]
18. [Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects].
Chenard-Neu MP; Bellocq JP; Maier A; Batzenschlager A
Ann Pathol; 1990; 10(1):20-7. PubMed ID: 2328062
[TBL] [Abstract][Full Text] [Related]
19. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L
J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489
[TBL] [Abstract][Full Text] [Related]
20. Detection of tissue CEA-like substance as an aid in the differential diagnosis of malignant mesothelioma.
Whitaker D; Sterrett GF; Shilkin KB
Pathology; 1982 Jul; 14(3):255-8. PubMed ID: 6290965
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
